Evidence map›Paper›PMID 40697667›Full record

ReviewFrontiers in pharmacology2025

Advancements in bladder cancer immunotherapy: a focus on intravesical approaches.

Xia Tang, Tianlun Yu, Hongxuan Tong, Yufan Wu

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xia Tang *Department of Urology, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu, China.
Tianlun Yu *Clinical Laboratory, Kunshan Rehabilitation Hospital, Kunshan, Jiangsu, China.
Hongxuan TongInstitute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Yufan WuDepartment of Urology, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in bladder cancer immunotherapy have shown promise, particularly in addressing limitations of the current gold standard,

Indexed as

bladder cancerimmune checkpoint inhibitorsimmunotherapyintravesical drug administrationmucosal immunityneoadjuvant immunotherapy trialsurinary bladder neoplasms

Identifiers

PMID40697667
PMCPMC12279809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.